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Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease caused by both genetic and envi-
ronmental factors. Genome scans in families with SLE point to multiple potential chromosomal regions that harbor
SLE susceptibility genes, and association studies in different populations have suggested several susceptibility alleles
for SLE. Increased production of type I interferon (IFN) and expression of IFN-inducible genes is commonly observed
in SLE and may be pivotal in the molecular pathogenesis of the disease. We analyzed 44 single-nucleotide poly-
morphisms (SNPs) in 13 genes from the type I IFN pathway in 679 Swedish, Finnish, and Icelandic patients with
SLE, in 798 unaffected family members, and in 438 unrelated control individuals for joint linkage and association
with SLE. In two of the genes—the tyrosine kinase 2 (TYK2) and IFN regulatory factor 5 (IRF5) genes—we identified
SNPs that displayed strong signals in joint analysis of linkage and association (unadjusted ) with SLE.57P ! 10
TYK2 binds to the type I IFN receptor complex and IRF5 is a regulator of type I IFN gene expression. Thus, our
results support a disease mechanism in SLE that involves key components of the type I IFN system.
Systemic lupus erythematosus (SLE [MIM 152700]) is
regarded as the prototypic systemic autoimmune disease;
it has a prevalence of 0.06% in white populations. SLE
is more common in women than in men and has a strong
heritable component, as shown by twin studies (Hoch-
berg 1987; Deapen et al. 1992). Typically, in SLE, im-
mune complexes are formed that consist of autoanti-
bodies against nucleic acids, ribonucleoproteins, and his-
tones. The immune complexes are considered to be the
principal cause of inflammation in SLE and give rise to
arthritis, skin rashes, nephritis, and vasculitis, among
other symptoms (Wallace and Hannahs 2002). Both ge-
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netic and environmental factors are thought to contrib-
ute to the continuous autoimmune process. In accordance
with the apparent multigenic character of SLE, genome-
wide scans point to multiple chromosomal regions that
potentially harbor SLE-susceptibility genes (Cantor et al.
2004), and association studies have suggested several sus-
ceptibility genes for SLE. For a review, see Tsao (2004).
Genes encoding haplotypes of the human leukocyte an-
tigen (HLA) complex, early components of the comple-
ment system, and low-affinity receptors for the Fc region
of IgG have shown association with SLE in multiple
populations. A polymorphism in the programmed cell
death 1 (PDCD1) gene appears to be associated with
SLE in Icelandic, Swedish, and Mexican patients (Proku-
nina et al. 2002). The proteins encoded by all these genes
may, in various ways, promote production of autoanti-
bodies and subsequent formation, tissue deposition, and
effects of immune complexes. The molecular pathogene-
sis of SLE, however, is still obscure.
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Table 1
Sample Overview
SAMPLE AND
LOCATION
NO. OF FAMILIES NO. OF SAMPLES
Multicase Single Case Affecteda Unaffected Total
Family:
Uppsala, Sweden 3 38 45 66 111
Lund, Sweden 3 128 146 376 522
Finland 37 72 150 237 387
Iceland 11 … 30 119 149
Unrelated:
Uppsala, Sweden … … 33 256 289
Lund, Sweden … … 15 … 15
Umea˚, Sweden … … 260 … 260
Finland … … … 182 182
Total 54 238 679 1,236 1,915
a There were 88%, 92%, and 88% females among the Swedish, Finnish, and
Icelandic patients, respectively. The age ( SD) at SLE diagnosis was 37.4  15.5
years in Sweden, years in Finland, and in Iceland (31.8  12.5 29.9  12.4 P p
). The mean number of ACR criteria observed in the patients was in.001 5.6  1.6
Sweden and in Finland. Information on ACR criteria was not available5.4  1.3
for the Icelandic patients.
The type I interferon (IFN) system has been proposed
as having a pivotal role in the development and main-
tenance of the disease process in SLE (Ro¨nnblom and
Alm 2003). The type I IFNs comprise a multigene family
with 13 IFN-a subtype genes and single genes encoding
IFN-b, -q, -, and -k (Levy et al. 2003). Patients with
SLE have increased serum IFN-a levels that correlate
with disease activity and severity, as well as with markers
of immune activation, such as levels of antibodies against
double-stranded DNA (dsDNA) and complement activa-
tion (Bengtsson et al. 2000). The type I IFNs act on a
common receptor, the IFN a receptor (IFNAR), resulting
in activation of the Janus kinases JAK1 and TYK2 and
several signal transducers and activators of transcription
(STAT1–6) (David 2002). This results in increased ex-
pression of a spectrum of type I IFN–inducible genes (de
Veer et al. 2001). Such an “IFN signature” of gene ex-
pression was observed in peripheral blood mononuclear
cells in patients with SLE and appears to be correlated
with the activity and severity of the disease (Baechler et
al. 2003; Crow and Wohlgemuth 2003). The reason for
the ongoing IFN-a production in SLE is probably acti-
vation of the plasmacytoid dendritic cells (PDC), also
termed “natural IFN-a–producing cells” (NIPC), by im-
mune complexes consisting of autoantibodies and auto-
antigens that contain DNA or RNA (Ba˚ve et al. 2000;
Lo¨vgren et al. 2004). Such autoantigens are formed via
the increased apoptosis and impaired scavenging of ap-
optotic cells in SLE (Kaplan 2004). Induction of IFN-a
gene expression by the immune complexes requires both
the Fc region of IgG that interacts with the Fc g receptor
IIa (FCGR2A) on NIPC/PDC (Ba˚ve et al. 2003) and RNA
or DNA that interacts with membrane-bound or intra-
cellular receptors (Akira and Takeda 2004; Yoneyama
et al. 2004). Activation of transcription factors, includ-
ing IFN regulatory factors 3, 5, and 7 (IRF3, IRF5, and
IRF7, respectively) is crucial for the expression of the
type I IFN genes (Barnes et al. 2002). The IFN-a pro-
duced by activated NIPC/PDC can promote autoim-
munity by stimulating key cells in the immune system,
including lymphocytes and antigen-presenting dendritic
cells (Stewart 2003). A causative role of IFN-a in SLE
is more directly indicated by the development of SLE
and other autoimmune diseases in tumor and in patients
with hepatitis during treatment with IFN-a (Ro¨nnblom
et al. 1991; Ioannou and Isenberg 2000). The disease
that certain patients develop during IFN-a treatment is
indistinguishable from spontaneously occurring SLE.
Furthermore, deletion of the Ifnar gene in lupus-prone
mice markedly reduces SLE disease and mortality (San-
tiago-Raber et al. 2003).
Given this proposed crucial role of the type I IFN
system in SLE, we dissected the function of the type I
IFN system in SLE by joint linkage and association an-
alysis of a panel of 11 genes encoding important type I
IFN signaling molecules in Swedish and Finnish patients
with SLE, their family members, and unrelated control
individuals. The analyzed genes encode the two IFNAR
subunits (IFNAR1 and IFNAR2), the two IFNAR-asso-
ciated protein tyrosine kinases (JAK1 and TYK2), two
signal transducers and activators of transcription (STAT1
and STAT3), an IFN regulatory factor (IRF5), an IFN
inducible protein (IFI1), and type I IFNs (IFNA21,
IFNA6, and IFNB1). Because of their connection to the
type I IFN system, the genes encoding FCGR2A and
PDCD1 were also included in the analysis. FCGR2A is
required for IFN-a production (Ba˚ve et al. 2003), and
the ligand of PDCD1, called “PDL1,” is upregulated by
IFN-a (Eppihimer et al. 2002).
The study subjects comprised a Swedish set of 499
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patients with SLE, 442 unaffected family members, and
256 unrelated controls, and a Finnish set of 150 patients
with SLE, 237 unaffected pedigree members, and 182
unrelated controls (table 1). The Swedish patients with
SLE and their family members were recruited from Lund,
Uppsala, and Umea˚ University hospitals. A group of 256
volunteer blood donors, including 60 individuals age-
and sex-matched to patients from Uppsala and a set of
182 anonymous Finnish population samples, served as
unrelated control individuals. The Finnish families with
SLE were recruited from the major hospitals in Finland
(Koskenmies et al. 2004). A set of 11 Icelandic families
with multicase SLE (Kristjansdottir et al. 2000) from the
Center for Rheumatology Research, in Reykjavik, were
analyzed to confirm our findings in the Swedish and
Finnish samples. The affected individuals fulfilled the
criteria for SLE defined by the American College of
Rheumatology (ACR) (Tan et al. 1982). Informed con-
sent was provided by each individual included in the
study. The samples were collected according to the Hel-
sinki Declaration. Ethical approvals for the study were
obtained from the ethics committees of each center.
First, we genotyped a panel of 33 SNPs in the candi-
date genes from the type I IFN pathway, by use of DNA
extracted from blood samples of the study subjects. The
SNPs were randomly selected from databases; their assay
performance had been validated in a previous study (Lin-
droos et al. 2002). The SNP rs1800593 (R/H131) in
FCGR2A (Karassa et al. 2002) and the SNP rs11568821
(PD-1.3) in PDCD1 (Prokunina et al. 2002) have been
associated elsewhere to SLE in Swedish patients (Proku-
nina et al. 2002; Magnusson et al. 2004). For genotyping
the SNPs, we used fluorescent minisequencing with an
“in-house” developed multiplex tag-array system (Lin-
droos et al. 2002), the 12-plex SNPStream system (Beck-
man Coulter) (Bell et al. 2002), or the homogeneous
template directed-dye terminator assay with fluores-
cence polarization detection (FP-TDI [Perkin Elmer]) for
individual SNPs (Hsu et al. 2001). We assessed the qual-
ity of the genotype data by testing for Hardy-Weinberg
equilibrium in the control samples, using Fisher’s exact
test ( ) and using the program Mendel (LangeP 1 .05
2001) to identify possible non-Mendelian inheritance of
alleles in the family samples. No significant deviation
from Hardy-Weinberg equilibrium and no Mendelian in-
heritance errors were observed for any of the SNPs in-
cluded in the study. The overall genotype call rate was
92%, and the accuracy was 199%, according to dupli-
cate genotyping of all samples and by repeated geno-
typing of 10 SNPs in the two most interesting genes in
all samples, with another of the three methods used.
Table 2 provides information about the SNPs and their
minor-allele frequencies. The allele frequencies for the
affected individuals given in table 2 are based on all
affected singleton individuals and one randomly selected
individual from each pedigree with SLE. We did not
observe any significant differences in allele frequencies
for any of the analyzed SNPs between affected individ-
uals from Umea˚ (northern Sweden), Uppsala (central
Sweden), and Lund (southern Sweden), nor between un-
affected pedigree members from Uppsala and Lund (data
not shown).
We performed joint linkage and association analysis
on individual SNPs, analyzing all of our genotype data
from pedigrees and singletons together (table 1), using
the software package Pseudomarker, which implements
penetrance model-based analogs of popular so-called
model-free methods for statistical gene localization (Go¨-
ring and Terwilliger 2000). The key advantage of Pseudo-
marker is that it extracts both the linkage and associa-
tion information from a data set. We analyzed the sam-
ples from Sweden and Finland separately, to avoid pos-
sible problems due to potential genetic differences be-
tween these populations. We used Fisher’s procedure for
combining P values from different data sets to derive
overall P values, using the analytical expression of Jost.
Table 2 shows the results from this analysis in a domi-
nant model of inheritance. We obtained strong signals
for joint linkage and association for one of the SNPs in
TYK2 (TYK2 rs2304256) and one of the SNPs in IRF5
(IRF5 rs2004640) in the Swedish and Finnish popula-
tions analyzed separately. Combination of the P values
from both populations increased significance further,
with P values of for TYK2 rs2304256 and73.4 # 10
for IRF5 rs2004640. To adjust the P values72.4 # 10
for multiple testing, we applied a Bonferroni correction
with each individual SNP as an independent variable.
Despite this conservative adjustment, our results re-
mained highly significant, with adjusted P values of
for TYK2 rs2304256 and for5 61.1 # 10 7.9 # 10
IRF5 rs2004640. An additional SNP in TYK2 (TYK2
rs12720356) resulted in a low P value (P p 5.5 #
; adjusted ) in the Swedish popula-4 210 P p 1.7 # 10
tion only. We were not able to reproduce the association
results for the SNPs in FCGR2A and PDCD1 in the
Swedish or Finnish samples. Analysis of linkage alone,
without allowance for association, did not reach signifi-
cance for any of the SNPs in either population, sepa-
rately or jointly (data not shown).
Given these results, we genotyped seven additional
SNPs in TYK2 and four additional SNPs in IRF5, and
we performed the same analyses as for the previous
SNPs. The results are included in table 2 (in which these
additional SNPs are footnoted). Two of the added IRF5
SNPs, rs729302 and rs752637, gave a nearly significant
signal in the Finnish samples. To verify our results, we
also performed case-control association analysis, using
Fisher’s exact test, for data from all singleton affected
individuals and one affected individual from each of the
pedigrees (480 Swedish and 109 Finnish subjects) and
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Figure 1 Schematic illustration of the structure of TYK2 and IRF5. The positions of exons are shown as numbered gray boxes, and the
translation initiation sites are shown by arrows on both genes. The positions of the 11 TYK2 SNPs and the 6 IRF5 SNPs analyzed in the study
are shown by vertical lines and dbSNP rs numbers. SNPs with low P values in joint linkage and association analysis in the Swedish and/or
Finnish sample sets are marked with an asterisk (*). The D′ and values for pairwise linkage disequilibrium for the TYK2 SNPs were calculated2r
from the genotypes of Swedish unrelated control individuals, and the D′ and values for the IRF5 SNPs were calculated from Finnish unrelated2r
control individuals, by use of the Haploview program (Barrett et al. 2005). nspnonsignificant.
unrelated control individuals (256 Swedish and 121
Finnish individuals). These results, also shown in table
2, confirm the results from our joint linkage and asso-
ciation analyses, albeit at slightly lesser significance. The
ORs were 1.6 (95% CI 1.3–1.9) for both the TYK2
rs2304256 and for the IRF5 rs2004640 SNP and sup-
port our association results obtained by Fisher’s exact
test. Figure 1 displays the positions of the 11 analyzed
SNPs on TYK2, the 6 analyzed SNPs on IRF5, and the
pairwise linkage-disequilibrium (LD) values between the
SNPs with low P values in either of the populations. The
LD-strength patterns are similar in both populations, as
shown in figure A1 (online only), which provides the
pairwise LD values for all genotyped TYK2 and IRF5
SNPs in Swedish and Finnish control samples. When we
used the Haploview program (Barrett et al. 2005), we
did not detect any statistically significant differences in
haplotype frequencies between the two populations, and
haplotype association analyses revealed no association
with SLE with higher statistical significance than analysis
of individual SNPs in either of the populations (data not
shown).
The IRF5 SNP rs2004640 and TYK2 SNP rs2304256
were also analyzed for joint linkage and association in
11 Icelandic families with multicase SLE. Table 3 gives
the unadjusted P values obtained in this analysis in the
Swedish, Finnish, and Icelandic populations, under domi-
nant and recessive models, with the overall P value de-
rived from the P values from the data sets from the three
individual countries. Both models gave similar results.
Inclusion of the Icelandic families in the analysis further
increased the significance of our findings by one order
of magnitude, with P values of for TYK284.2 # 10
rs2304256 and for IRF5 rs2004640 under81.5 # 10
the dominant model, and with P values of 72.0 # 10
for TYK2 rs2304256 under a recessive model. Inclusion
of the Icelandic families did not increase the significance
of our findings for IRF5 rs2004640 under the recessive
model.
The frequencies of the rare A allele of TYK2
rs2304256 (A/C) and the rare C allele of IRF5
rs2004640 (C/A) are lower in the Swedish and Finnish
patients with SLE than in the corresponding controls
(table 2). We used logistic regression analysis to correlate
the genotypes of these SNPs in TYK2 and IRF5, with
the ACR classification criteria (Tan et al. 1982) fulfilled
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Table 3
Pseudomarker Analysis of SNPs TYK2 rs2304256 and IRF5 rs2004640 in the Swedish, Finnish, and Icelandic Populations,
in Dominant and Recessive Models
MODEL AND
DBSNP RS NUMBER
P VALUESa FOR
Joint Linkage and Association Linkage Only
Sweden Finland Icelandb Combinedc Sweden Finland Iceland Combinedc
Dominant:
TYK2 rs2304256 61.0 # 10 .018 34.1 # 10 82.2 # 10 .23 .23 .063 .077
IRF5 rs2004640 58.5 # 10 41.5 # 10 .015 85.2 # 10 .50 .35 35.4 # 10 .031
Recessive:
TYK2 rs2304256 52.5 # 10 46.0 # 10 .054 72.0 # 10 .50 .17 .32 .30
IRF5 rs2004640 48.1 # 10 44.1 # 10 .25 51.2 # 10 .50 .42 .3 .49
NOTE.—The P values obtained in a dominant model in the Swedish and Finnish populations are identical to the values in
table 2. The combined P values in the Swedish and Finnish populations were for TYK2 rs2304256 and7 73.4 # 10 2.4 # 10
for IRF5 rs2004640 in a dominant model (table 2) and were for TYK2 rs2304256 and for IRF5 rs20046407 62.8 # 10 5.2 # 10
in a recessive model.
a P values are unadjusted for multiple testing.
b In the Icelandic patients with SLE, the frequency of the minor allele (C allele) of IRF5 rs2004640 was .43, and that of the
minor allele (A allele) of TYK2 rs2304256 was .14.
c Fisher’s procedure for combination of P values from different data sets was used to derive overall P values, by use of the
analytical expression of Jost.
by the patients with SLE and with the presence of anti-
dsDNA antibodies. This analysis revealed no significant
correlation between the TYK2 or IRF5 genotypes and
ACR criteria, although there was a tendency of associa-
tion of the rare A allele of TYK2 rs2304256 with re-
duced occurrence of lupus nephritis (ACR criterion 7)
in the Swedish patients ( ) and of the rare CP p .026
allele of IRF5 rs2004640 with reduced occurrence of
CNS involvement (ACR criterion 8) in Finnish patients
( ). The data from the logistic regression analy-P p .023
sis are provided in table A1 (online only). Obviously,
this analysis must be applied to a larger number of pa-
tients. It is, however, possible that the TYK2 and IRF5
genes are more generally involved in development of SLE
via multiple effects, particularly on the type I IFN sys-
tem, than with the specific manifestations represented
by the ACR criteria. The latter may well be controlled
by other genes. The TYK2 gene is located on chromo-
some 19p13.2, and, interestingly, this locus has been
linked to SLE in white pedigrees stratified by the pres-
ence of anti-dsDNA antibodies (Namjou et al. 2002).
Moreover, the A allele of the intronic SNP PD-1.3 in the
PDCD1 gene (Prokunina et al. 2002) was recently found
to be associated with a reduced occurrence of anti-
phospholipid antibodies both in patients with SLE and
in the general population (Sanghera et al. 2004). The
IRF5 gene is located on chromosome 7q32, a region
lacking previously published linkage results.
The Janus kinase TYK2 consists of seven JAK-homolo-
gy (JH) regions. The SNP TYK2 rs2304256 is located in
exon 8 of the gene, where the rare A allele of this SNP
causes a substitution of ValrPhe at position 362 in the
JH4 region of TYK2. This region is part of a larger
domain of TYK2 that is crucial not only for the inter-
action of TYK2 with IFNAR1 and its function (Richter
et al. 1998) but also for maintaining expression of
IFNAR1 on cell membranes (Ragimbeau et al. 2003).
The ValrPhe substitution in TYK2 is characterized as
“benign,” according to the PolyPhen (polymorphism
phenotyping) and “intolerant” according to the SIFT
(sorting intolerant from tolerant) programs, respectively
(as described at the University of Washington–Fred
Hutchinson Cancer Research Center SeattleSNPs Web
site). The TYK2 rs12720356 SNP causes a substitution
of IlerSer at amino acid position 684 in the pseudo-
kinase region JH2 of TYK2. The IlerSer substitution is
predicted to be “damaging” and “intolerant” by the Poly-
Phen and SIFT tools, respectively. The JH2 region of
TYK2 is required for binding of type I IFN to IFNAR1,
but it does not influence the expression of IFNAR1 (Yeh
et al. 2000). Although we originally selected TYK2 for
study because of its connection with the type I IFN sys-
tem, it should be noted that TYK2 also interacts with
the receptors for colony stimulating factor 1, angiotensin
II, platelet-activating factor, and several interleukins (Kis-
seleva et al. 2002). Thus, an altered function of TYK2
may well also affect other cytokines, such as IL-10, for
which an association to SLE has been reported (Chong
et al. 2004). The importance of TYK2 in autoimmunity
is also supported by the finding that Tyk2-deficient mice
are resistant to experimental arthritis (Shaw et al. 2003).
Consequently, we speculate that the amino acid sub-
stitutions caused by the TYK2 SNPs (rs2304256 and
rs12720356) may reduce the function of TYK2, result-
ing in a decreased susceptibility to SLE.
IRF5 is one of the nine so-far-identified members of
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the IRF family that, together with IRF3 and IRF7, play
an important role in the innate immune response by
inducing type I IFN production during viral infections
(Barnes et al. 2002). IRF5 is constitutively expressed
mainly in cells of the immune system, particularly in
NIPC, monocytes, and monocyte-derived dendritic cells,
as well as in B cells (Izaguirre et al. 2003). Expression
of IRF5 can be enhanced by type I IFN (Barnes et al.
2001). IRF5 is phosphorylated in cells upon viral infec-
tions and translocates to the nucleus, which results in
activation of a spectrum of IFN-a genes that differ from
those activated by IRF3 and IRF7 (Barnes et al. 2004).
IRF5 also increases the expression of many genes other
than the type I IFN genes, such as genes coding for
signaling molecules, proteins involved in cell signaling,
apoptosis, cell-cycle regulation, and early immune re-
sponse. The IRF5 gene may be directly upregulated by
p53, which indicates that IRF5 can be a p53-dependent
mediator of the control of cell cycle and apoptosis (Mori
et al. 2002; Barnes et al. 2003). Thus, polymorphism
within the IRF5 gene may affect several cellular func-
tions of importance for the development of an auto-
immune disease such as SLE. The IRF5 SNP rs2004640
is the first nucleotide of IRF5 intron 1 and may thus
have a functional role by altering the splicing of exon 1
of the IRF5.
In conclusion, by analyzing candidate genes from the
type I IFN system, we identified polymorphisms in the
TYK2 and IRF5 genes that displayed strong signals of
joint linkage and association with SLE. The possible con-
sequences of the identified SNPs on the function or ex-
pression levels of TYK2 and IRF5 remain to be eluci-
dated experimentally. Our finding that genes involved in
both the production of type I IFN and response to these
cytokines are associated with SLE further strengthens
the view that the type I IFN system is pivotal in the
etiopathogenesis of this autoimmune disease. The results
are also remarkable because we analyzed only 11 genes,
selected on the basis of their connection with the type I
IFN system. In fact, 1200 genes may be involved in the
activation and regulation of the type I IFN system and
as mediators of the effects of IFN. We anticipate that
several other genes within the type I IFN system are
associated with SLE and possibly also other autoimmune
disorders.
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